#USA #Fremont #Alamar Biosciences #NULISAseq #pTau Assays

Alamar Biosciences Enhances NULISAseq™ CNS Disease Panel 120

Alamar Biosciences has made a significant enhancement to its NULISAseq™ CNS Disease Panel 120, which brings novel assays into the realm of neurodegenerative disease research. The expansion includes advanced assays for brain-derived phosphorylated tau (pTau) proteins, specifically targeting pTau217, pTau181, pTau231, and total tau (tTau). This addition marks an essential leap forward in the pursuit of actionable biomarkers for conditions like Alzheimer's disease.

The significance of phosphorylated tau proteins as key indicators in the early detection and ongoing monitoring of Alzheimer's and tauopathies is increasingly recognized in the scientific community. The newly integrated assays set themselves apart by their capacity to conclusively identify brain-derived forms of pTau directly from blood samples. This capability overcomes a longstanding hurdle faced by researchers: the inability to differentiate between tau proteins originating from peripheral circulation and those derived from the central nervous system.

One of the most groundbreaking aspects of the expanded panel lies in its ability to conduct multiplexed measurements effectively. Alamar's NULISAseq panel can now provide insights into two distinct groups of tau species—one specifically for those derived from the brain and another that encompasses both brain and peripheral-derived tau. This dual approach allows for a more comprehensive analysis of tau pathology, offering researchers unprecedented precision in their studies.

Dr. Yuling Luo, the CEO and Founder of Alamar Biosciences, articulated the innovation's potential impact: “Researchers have long sought a reliable, blood-based solution to track brain-derived tau pathology. By boosting our NULISAseq CNS Disease 120 Panel with assays for multiple phosphorylated tau proteins, we are empowering scientists to explore the intricacies of tau pathology with remarkable sensitivity and efficiency.”

Furthermore, Nicholas Ashton, Ph.D., who heads Neurodegenerative Biomarker Research at Banner Health, echoed the panel's transformative potential. He noted, “The ability to detect brain-derived pTau species directly from the blood represents a transformative step in the early detection and monitoring of Alzheimer's Disease and related disorders.” With this enhanced capability, the panel aims to improve diagnostic accuracy significantly, ensuring better outcomes in patient care and clinical research settings.

Alamar Biosciences emphasizes its commitment to collaboration with the neuroscience community, aiming to unlock insights that will facilitate earlier diagnosis, improved patient stratification, and better therapeutic monitoring for neurodegenerative diseases.

For further details about the NULISAseq CNS Disease Panel 120 and to explore Alamar Biosciences' range of proteomic solutions, visit Alamar's official website.

About Alamar Biosciences, Inc.

Alamar Biosciences is a forward-thinking life sciences enterprise with a resolute mission to propel precision proteomics for early disease detection. Its proprietary NULISA Platform, working in tandem with the ARGO™ HT System, achieves unparalleled detection sensitivity, far exceeding existing technologies in the protein detection landscape. To learn more about Alamar and its innovations, visit alamarbio.com.